Addex Reports Q1 2023 Financial Results and Provides Corporate Update
May 11, 2023 01:00 ET
|
Addex Therapeutics
ADX71149 Phase 2 epilepsy clinical study’s independent interim review committee (“IRC”) recommends continuing study CHF 5.6M ($ 6.1M) of cash and cash equivalents at March 31, 2023 Ad Hoc...
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study
May 10, 2023 01:00 ET
|
Addex Therapeutics
Cohort 1 progressing through Part 2Cohort 2 recruiting patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a...
Addex Convenes Annual General Meeting 2023
May 05, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023
May 04, 2023 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 4, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex Completes $5.0 Million Equity Financing
April 05, 2023 01:00 ET
|
Addex Therapeutics
Proceeds to advance allosteric modulator therapeutic pipeline Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 5, 2023 – Addex Therapeutics Ltd (SIX: ADXN and...
Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease
April 04, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 4, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Raises $5.0 Million in Equity Financing
April 03, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 3, 2023 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Reports Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 01:00 ET
|
Addex Therapeutics
CHF 7.0M ($ 7.4M) of cash and cash equivalents at December 31, 2022ADX71149 Phase 2 study in epilepsy cohort 1 completes part 1 – independent interim review committee (IRC) recommendation expected...
Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
March 28, 2023 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, March 28, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex Announces Upcoming Conferences it will participate for H1 2023
March 16, 2023 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, March 16, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...